Re:flux and the Rise of Polyphenol-Based Reflux Management: A Systems Biology Approach to GERD Relief

Aim: To situate a polyphenol-based nutraceutical (combining hesperidin, noni, dandelion root, and Atractylodes macrocephala extracts) within a systems-biology framework for GERD management, using mixed-methods data from patients and healthcare providers, and contextualizing findings with previously reported clinical outcomes.

Methods: A mixed-methods evaluation was conducted including: (1) a survey of 160 adults with recurrent reflux symptoms; (2) a survey of 54 healthcare providers (HCPs) in gastroenterology-adjacent and integrative practice; and (3) four in-depth qualitative interviews with long-term PPI users who transitioned to a polyphenol-based nutraceutical. Findings were interpreted alongside results from a previously conducted open-label comparative study of the same nutraceutical in 47 chronic GERD patients versus historic standard-of-care controls (reported separately as Brown et al., submitted).

Results: Among surveyed patients, most reported significant lifestyle impact from reflux, high reliance on PPIs or acid-suppressive therapies, and concern about long-term medication safety. Two-thirds expressed interest in evidence-based natural options addressing root causes. HCPs reported difficulty deprescribing PPIs, frustration with rebound symptoms, and a strong willingness to recommend nutraceuticals if supported by clinical data and mechanistic plausibility. Interview participants described substantial emotional burden, loss of agency, and a sense of “treating acid, not the problem” while on PPIs; after transitioning to the polyphenol formulation, they reported improved sleep, greater dietary freedom, and renewed confidence in long-term management. A separate prospective open-label comparative study of this formulation in 47 chronic GERD patients demonstrated high rates of symptom resolution and PPI discontinuation compared with standard therapy (Brown et al., submitted), providing clinical context for these experiential findings.

Conclusion: Patients and clinicians are actively seeking GERD therapies that move beyond acid suppression toward restoration of motility, barrier function, and inflammatory balance. Polyphenol-based nutraceuticals such as the hesperidin–noni–dandelion–Atractylodes formulation evaluated here appear to align with this systems-biology paradigm. Mixed-methods data, together with emerging clinical evidence, support further investigation of polyphenol-driven reflux management in rigorous controlled trials.

Introduction

Gastroesophageal reflux disease (GERD) is among the most common gastrointestinal disorders worldwide, with prevalence estimates in Western populations approaching 20% and rising trends globally.¹,² Many patients experience chronic or recurrent symptoms, including heartburn, regurgitation, and epigastric pain, and a substantial subset report ongoing discomfort despite standard therapy.²,³

PPIs remain the first-line pharmacologic treatment for GERD because of their potent and predictable acid suppression.¹¹ However, GERD pathophysiology is multifactorial: transient LES relaxations, impaired sphincter tone, delayed gastric emptying, hiatal hernia, and altered esophageal clearance all contribute to acid exposure and symptom generation.⁵–⁷,²³ In this context, PPI therapy targets only one dimension—acid production—without directly correcting motility, barrier function, or sensory hypersensitivity.²³

Concerns regarding long-term PPI use have grown in recent years. Observational studies and expert reviews have linked chronic PPI exposure with nutrient malabsorption (e.g., vitamin B₁₂ deficiency), renal complications, enteric infections, and potential cognitive risks.⁶,⁷,⁴,¹⁰ Although causality remains debated for some outcomes, the cumulative safety signal has encouraged clinicians and patients to reconsider indefinite acid suppression and to explore approaches that restore physiological function rather than simply suppressing gastric acid.⁶,²³

Non-pharmacologic strategies, including dietary modification, weight loss, meal timing changes, and behavioral interventions, can ameliorate symptoms but are challenging to maintain in real-world practice.¹⁶,²⁵ Many patients continue to seek additional options, turning toward complementary and alternative therapies, including nutraceuticals and botanicals.¹⁶,²⁶

Polyphenol-based nutraceuticals have attracted particular interest due to their capacity to modulate oxidative stress, inflammatory signaling, motility, and mucosal integrity.¹⁸,¹⁹,²⁰–³⁴ A defined combination of hesperidin, noni fruit (Morinda citrifolia), dandelion root (Taraxacum officinale), and Atractylodes macrocephala extracts was formulated to target multiple nodes in GERD pathophysiology, including LES tone, gastric emptying, mucosal defense, and local inflammatory tone. Preclinical and translational work supports relevant actions of each component individually, including effects on pacemaker activity, cytokine modulation, gastroprotection, and motility.¹⁸–²¹,²⁷–³⁴

A prospective, open-label comparative study in a community gastroenterology practice evaluated this polyphenol combination in 47 chronic GERD patients versus a historic standard-of-care group, demonstrating substantial symptom improvement and reduced reliance on PPIs. That clinical study, which focuses on efficacy and safety outcomes, is reported separately (Brown et al., submitted).

The present paper has a different aim: to place this polyphenol-based approach within a systems-biology framework for GERD, integrating patient and provider perspectives, lived experience, and mechanistic plausibility. Using mixed-methods data—including patient surveys, clinician surveys, and qualitative interviews—we explore how a nutraceutical strategy such as Re:flux may respond to unmet needs in reflux care, and how emerging polyphenol data might support a shift from pure acid suppression toward physiological restoration.

Methods

Study Design

This work employed a mixed-methods design combining quantitative surveys, qualitative interviews, and contextual interpretation of previously collected clinical outcome data. The focus of this paper is on attitudes, experiences, and mechanistic framing, not on presenting a new clinical trial.

Four data streams were included:

1. Patient survey of adults with recurrent reflux symptoms

2. Healthcare provider (HCP) survey of clinicians managing reflux in clinical practice

3. Qualitative patient interviews with individuals who transitioned from long-term PPI therapy to the polyphenol-based nutraceutical

4. Contextual reference to outcomes from an open-label comparative study of the nutraceutical formulation in chronic GERD patients (Brown et al., submitted)

Internal surveys, interviews, and observational data are original to this program and do not require external citation. They are described here as primary data.

Patient Survey

A cross-sectional survey was distributed to 160 adults who self-identified as experiencing recurrent heartburn, reflux, or GERD-like symptoms. The survey captured:

• Symptom burden and impact on daily life (sleep, social activities, food enjoyment)

• History of pharmacologic treatment, including PPI and H2 receptor antagonist use

• Perceived benefits and drawbacks of current therapies

• Awareness of safety concerns related to long-term PPI use

• Interest in natural or nutraceutical therapies, particularly those with clinical evidence

Responses included structured multiple-choice items and optional short free-text responses. Data were summarized descriptively.

Healthcare Provider Survey

A separate survey was administered to 54 clinicians, including gastroenterologists, integrative medicine physicians, naturopathic doctors, and functional/holistic practitioners who regularly encounter GERD. Items explored:

• Perceived challenges in GERD management

• Experience with PPI-refractory or partially responsive patients

• Comfort level and barriers in tapering PPIs

• Attitudes toward nutraceuticals and botanical therapies

• Requirements for recommending such therapies (e.g., clinical data, mechanistic rationale, quality and transparency of ingredients)

Responses were summarized as proportions and thematic groupings.

Qualitative Interviews

Four semi-structured interviews were conducted with adults who had a history of long-term PPI use and transitioned to the polyphenol-based nutraceutical as part of their reflux management. Interviews explored:

• Emotional and psychosocial impact of living with chronic reflux

• Experiences on PPI therapy (benefits, limitations, identity as a “chronic patient”)

• Motivations for seeking a natural or non-suppressive option

• Perceived changes after initiating the nutraceutical (symptoms, sleep, diet, confidence, sense of agency)

Interviews were recorded, transcribed, and analyzed thematically to identify recurring motifs and narrative patterns.

Contextual Clinical Outcomes

Clinical outcomes from a practice-based, open-label comparative study of the same nutraceutical formulation in 47 chronic GERD patients, compared with historic controls on standard therapy, have been reported separately (Brown et al., submitted). Briefly, that study examined symptom resolution, PPI discontinuation rates, and tolerability over four weeks of use. In this paper, those results are referenced descriptively to contextualize patient and clinician perceptions but are not reanalyzed or presented as new data.

Results

Patient Survey (n = 160)

Most respondents reported that reflux symptoms affected multiple aspects of their lives. Common themes included:

• Lifestyle and psychosocial impact: Participants described avoiding social events involving food, reducing or eliminating favorite foods, and experiencing anxiety around meals and bedtime.

• Sleep disruption: Nighttime symptoms and positional reflux were frequently reported, contributing to fatigue and next-day impairment.

• Medication patterns:

• 61% reported current or prior PPI use

• Many had cycled on and off medications due to perceived side effects, incomplete relief, or concern about long-term safety

• Safety concerns: More than two-thirds of PPI users expressed worry about potential long-term consequences, especially after encountering media reports or online information about kidney disease, infections, and nutrient deficiencies.

• Interest in alternatives: 66% indicated that they would be interested in trying a clinically studied natural product that addressed “root causes” (motility, LES function, inflammation) rather than only acid.

Qualitative comments reinforced a sense of frustration with “managing acid forever” and a desire for therapies that “help my body work better, not just shut something off.”

Healthcare Provider Survey (n = 54)

Clinician responses highlighted the practical challenges of GERD management in real-world practice:

• PPI dependence and deprescribing difficulties:

• 67% reported that tapering or discontinuing PPIs was “difficult” or “very difficult” in their patient population, primarily due to rebound symptoms and patient fear.

• Recognition of unmet needs:

• Many respondents felt that current guidelines remain heavily acid-centric and do not fully address motility or mucosal healing.

• Openness to nutraceuticals:

• 89% would consider recommending a natural or botanical therapy if:

• It had plausible mechanisms tied to GERD pathophysiology

• There was clinical outcome data, even from practice-based or pilot studies

• Product quality and ingredient transparency were assured

• Desired mechanisms:

• 63% specifically cited a need for interventions that support gastric motility and LES integrity, not just acid suppression.

Several clinicians expressed that their GERD patients “want out of the lifelong PPI story” but that they, as providers, feel limited by the available tools.

Qualitative Interviews (n = 4)

The interviews revealed layered emotional and experiential themes:

• Burden of chronicity: Participants described feeling “stuck on medication forever” and worried about cumulative risk. Reflux was experienced not just as physical discomfort, but as a persistent threat that shaped food choices, social participation, and sleep.

• Skepticism and fatigue: After years on PPIs with residual or recurrent symptoms, participants felt resigned to “managing, not healing” and skeptical that anything new could make a meaningful difference.

• Transition to the polyphenol formulation: Motivations included concern about long-term PPI use, interest in more natural options, and trust in the physician recommending the nutraceutical.

• Reported changes: Participants described:

• Improved sleep and fewer nighttime awakenings

• Increased dietary freedom (more tolerated foods, less fear around triggers)

• A sense that their reflux was “quieter,” with fewer flare-ups

• Renewed confidence and agency in managing their condition

One participant described the experience as “the first time something felt like it was working with my system instead of just shutting things down.”

Clinical Outcomes in Context (Brown et al., submitted)

In a separate open-label comparative study conducted in the same practice, 47 chronic GERD patients who had not achieved satisfactory relief with conventional therapy received the hesperidin–noni–dandelion–Atractylodes formulation for four weeks and were compared with historic matched controls on standard therapy, predominantly PPIs. The nutraceutical cohort showed high rates of symptom resolution and substantial reductions in reliance on acid-suppressive medications, with acceptable tolerability and no serious adverse events reported.

While the full methodology and statistical findings of that study are detailed elsewhere, its results provide an important clinical backdrop to the attitudinal and experiential data presented here: patients’ and clinicians’ openness to polyphenol-based therapy is supported by early practice-based evidence indicating meaningful symptom improvement and PPI deprescribing feasibility.

Discussion

This mixed-methods analysis highlights a convergence of factors driving interest in alternative GERD therapies: persistent symptom burden, concern about long-term PPI exposure, and a desire—among both patients and clinicians—to move beyond a purely acid-suppression paradigm. Together with emerging clinical evidence from a polyphenol-based formulation, these findings underscore the potential of systems-biology approaches in reflux management.

From Acid Suppression to Systems Thinking

Current GERD care is anchored in PPIs, which remain highly effective for many patients, particularly in the short term.¹,¹¹ Yet a significant proportion experience persistent or recurrent symptoms even on therapy, and a substantial fraction report dissatisfaction or partial relief.²,¹⁰,²⁴ Adherence to lifestyle interventions is variable, and real-world patients often struggle to sustain dietary and behavioral changes needed to support long-term symptom control.¹⁶,²⁵

Pathophysiologic models of GERD increasingly emphasize that acid is necessary but not sufficient to explain disease burden. LES dysfunction, transient sphincter relaxations, delayed gastric emptying, hiatal hernia, impaired clearance, and visceral hypersensitivity all contribute to symptom generation and mucosal injury.⁵–⁷,⁶,²³ As Sharma and Yadlapati note, effective management may require “looking beyond acid” to target motility, barrier function, and inflammatory signaling.²³

Our patient and clinician surveys mirror these conceptual shifts. Patients articulated frustration with “treating acid but not the problem,” while clinicians reported difficulty tapering PPIs and a desire for tools that support motility and mucosal health. This aligns with literature documenting residual symptom burden and patient dissatisfaction despite widely available acid-suppressive therapy.²,²⁴,²⁵

Polyphenols as Multi-Node Modulators

Polyphenols are attractive candidates for systems-biology interventions in GERD because they can act at multiple levels of gastrointestinal function.¹⁸–²¹,²⁷–³⁴ The hesperidin–noni–dandelion–Atractylodes formulation discussed here was designed to leverage complementary mechanisms:

• Hesperidin, a citrus flavonoid, has been shown to modulate pacemaker potentials in interstitial cells of Cajal via 5-HT₄ receptor pathways, supporting motility, and to exert gastroprotective effects in ulcer models via anti-inflammatory and antioxidant actions.²⁷–²⁹

• Noni (Morinda citrifolia) extracts have demonstrated protection in reflux esophagitis and gastric ulcer models, as well as gastrokinetic effects linked to serotonergic and cholinergic pathways.³⁰,³¹ Human studies suggest broader anti-inflammatory and antioxidant benefits that may support mucosal healing.²⁰

• Dandelion root (Taraxacum officinale) and its principal phytochemical taraxasterol have been associated with decreased pro-inflammatory cytokines and mediators, gastroprotection in acute and chronic gastritis models, and enhanced gastric emptying and smooth muscle motility in rodents.²¹,²²,³²–³⁴

• Atractylodes macrocephala, traditionally used in East Asian medicine for digestive support, has a growing evidence base documenting effects on gastric motility, mucosal protection, and modulation of inflammatory signaling, including NF-κB–related pathways.¹⁹,³⁵–³⁹

Taken together, these findings support the plausibility of a formulation that simultaneously influences LES function, gastric emptying, mucosal defense, and inflammatory tone—precisely the domains that a systems-biology view of GERD identifies as key leverage points.

Complementing Other Non-PPI Strategies

Existing non-PPI reflux therapies often rely on mechanical or coating mechanisms. Alginate-based formulations, for example, can displace or neutralize the postprandial “acid pocket” and have shown non-inferiority to PPIs in some nonerosive reflux disease populations.⁴⁰–⁴² Aloe vera and other demulcent botanicals have demonstrated preliminary benefit in pilot trials, and polyphenol-rich extracts such as GutGard® have shown promise in managing upper GI symptoms, including reflux-related complaints.⁴³,⁴⁴

The polyphenol combination described here differs in emphasis. Rather than primarily coating or buffering, it is designed to modulate motility and mucosal biology from within, aligning more closely with integrative and functional frameworks that seek to restore physiological patterns of motility and defense.¹¹,²³,²⁶

Integrating Patient Experience and Clinical Signal

The practice-based comparative study (Brown et al., submitted) provides early evidence that this polyphenol formulation can deliver meaningful symptom relief and facilitate PPI deprescribing in a real-world cohort. Our survey and interview data help explain why such an approach resonates:

• Patients are motivated not only by symptom relief, but by a desire for agency, safety, and coherence—a sense that their treatment aligns with how they understand their body and long-term health.

• Clinicians express caution but readiness: they are willing to recommend nutraceuticals when mechanisms are plausible, data are available, and product quality is clear.

By bringing together clinical outcomes, mechanistic plausibility, and lived experience, this systems-biology perspective may help bridge the gap between conventional GERD management and the integrative strategies many patients are already seeking.

Limitations

This work has several limitations. The surveys and interviews represent a specific population of patients and providers who are already engaged with integrative or gastroenterology-focused care, which may limit generalizability. Self-reported data are subject to recall and selection bias. The practice-based clinical study referenced here was open-label and comparative rather than randomized and double-blind, and detailed results are reported elsewhere.

Nevertheless, the integration of quantitative, qualitative, and practice-based findings offers a valuable exploratory view of how polyphenol-based strategies may function within a broader GERD care ecosystem. Future research should include randomized controlled trials with validated outcome measures, mechanistic endpoints (e.g., pH-impedance, motility studies), and longer-term follow-up to evaluate durability and potential disease-modifying effects.

Conclusion

GERD remains a complex, multi-factorial condition that is incompletely addressed by acid suppression alone. As concerns about long-term PPI use grow and patients seek more holistic solutions, there is a clear need for therapies that work with, rather than against, gastrointestinal physiology.

Polyphenol-based nutraceuticals, such as the hesperidin–noni–dandelion–Atractylodes formulation evaluated in this work, offer a promising systems-biology approach—targeting motility, mucosal defense, and inflammatory tone while allowing acid to retain its physiological role. Mixed-methods findings from patients and clinicians, together with emerging practice-based clinical data, suggest that such strategies may play an important role in the future of GERD management.

Carefully designed, controlled studies are now warranted to confirm efficacy, clarify mechanisms, and define how polyphenol formulations can be integrated into stepwise GERD care alongside lifestyle interventions, pharmaceuticals, and, when needed, procedural options.

References 

1. Azer SA, Hashmi MF, Reddivari AKR. Gastroesophageal Reflux Disease (GERD). In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025–. Updated 2024 May 1. PMID: 32119349.

2. Delshad SD, Almario CV, Chey WD, Spiegel BMR. Prevalence of gastroesophageal reflux disease and proton pump inhibitor-refractory symptoms. Gastroenterology. 2020;158(5):1250–1261.e2.

3. El-Serag H, Becher A, Jones R. Systematic review: persistent reflux symptoms on proton pump inhibitor therapy in primary care and community studies. Aliment Pharmacol Ther. 2010;32(6):720–37.

4. Lazarus B, Chen Y, Wilson FP, et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med. 2016;176(2):238–46.

5. Castell DO, Murray JA, Tutuian R, Orlando RC, Arnold R. The pathophysiology of gastro-oesophageal reflux disease—oesophageal manifestations. Aliment Pharmacol Ther. 2004;20 Suppl 9:14–25.

6. Usai Satta P, Oppia F, Cabras F. Overview of pathophysiological features of GERD. Minerva Gastroenterol Dietol. 2017;63(3):184–97.

7. El-Serag HB, Ergun GA, Pandolfino J, et al. Obesity increases oesophageal acid exposure. Gut. 2007;56(6):749–55.

8. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R; Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101(8):1900–20.

9. Gomm W, von Holt K, Thomé F, et al. Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. JAMA Neurol. 2016;73(4):410–6.

10. Freedberg DE, Kim LS, Yang YX. The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice. Gastroenterology. 2017;152(4):706–15.

11. Yadlapati R, Gyawali CP, Pandolfino JE; CGIT GERD Consensus Conference Participants. AGA Clinical Practice Update on the personalized approach to the evaluation and management of GERD: expert review. Clin Gastroenterol Hepatol. 2022;20(5):984–994.e1.

12. Sethi S, Richter JE. Diet and gastroesophageal reflux disease: role in pathogenesis and management. Curr Opin Gastroenterol. 2017;33(2):107–11.

13. Bucan JI, Braut T, Krsek A, Sotosek V, Baticic L. Updates in gastroesophageal reflux disease management: from proton pump inhibitors to dietary and lifestyle modifications. Gastrointest Disord. 2025;7(2):33.

14. van Zanten SJ, Henderson C, Hughes N. Patient satisfaction with medication for gastroesophageal reflux disease: a systematic review. Can J Gastroenterol. 2012;26(4):196–204.

15. Guadagnoli L, Simons M, McGarva J, Taft TH, van Tilburg MAL. Improving patient adherence to lifestyle changes for the management of gastroesophageal reflux. Patient Prefer Adherence. 2022;16:897–909.

16. Sharma P, Yadlapati R. Pathophysiology and treatment options for gastroesophageal reflux disease: looking beyond acid. Ann N Y Acad Sci. 2021;1486(1):3–14.

17. Wei M, Chai Y, Shen H, et al. Efficacy and safety of Aurantii Fructus Immaturus flavonoid tablets vs domperidone for functional dyspepsia: a multicenter, double-blind, double-dummy, randomized controlled phase III trial. Acta Gastroenterol Belg. 2024;87(4):484–93.

18. Jun X, Fu P, Lei Y, Cheng P. Pharmacological effects of medicinal components of Atractylodes lancea (Thunb.) DC. Chin Med. 2018;13:59.

19. Yang L, Yu H, Hou A, et al. A review of the ethnopharmacology, phytochemistry, pharmacology, application, quality control, processing, toxicology, and pharmacokinetics of the dried rhizome of Atractylodes macrocephala. Front Pharmacol. 2021;12:727154.

20. West BJ, Deng S, Isami F, Uwaya A, Jensen CJ. The potential health benefits of noni juice: a review of human intervention studies. Foods. 2018;7(4):58.

21. Yang HJ, Kim MJ, Kwon DY, et al. Gastroprotective actions of Taraxacum coreanum Nakai water extracts in ethanol-induced rat models of acute and chronic gastritis. J Ethnopharmacol. 2017;208:84–93.

22. Uslu H, Uslu GA. Gastroprotective effects of Taraxacum officinale (dandelion) extract in an indomethacin-induced gastric ulcer model. GSC Biol Pharm Sci. 2022;20(3):74–81.

23. Hwang M, Kim JN, Kim BJ. Hesperidin depolarizes the pacemaker potentials through 5-HT₄ receptor in murine small intestinal interstitial cells of Cajal. Anim Cells Syst (Seoul). 2020;24(2):84–90.

24. Selmi S, Rtibi K, Grami D, Sebai H, Marzouki L. Protective effects of orange (Citrus sinensis L.) peel aqueous extract and hesperidin on oxidative stress and peptic ulcer induced by alcohol in rat. Lipids Health Dis. 2017;16(1):152.

25. Elshazly SM, Abd El Motteleb DM, Ibrahim IAAE. Hesperidin protects against stress-induced gastric ulcer through regulation of peroxisome proliferator activator receptor gamma in diabetic rats. Chem Biol Interact. 2018;291:153–61.

26. Mahattanadul S, Ridtitid W, Nima S, et al. Effects of Morinda citrifolia aqueous fruit extract and its biomarker scopoletin on reflux esophagitis and gastric ulcer in rats. J Ethnopharmacol. 2011;134(2):243–50.

27. Nima S, Kasiwong S, Ridtitid W, Thaenmanee N, Mahattanadul S. Gastrokinetic activity of Morinda citrifolia aqueous fruit extract and its possible mechanism of action in human and rat models. J Ethnopharmacol. 2012;142(2):354–61.

28. Jiao F, Tan Z, Yu Z, et al. The phytochemical and pharmacological profile of taraxasterol. Front Pharmacol. 2022;13:927365.

29. Li Y, Chen Y, Sun-Waterhouse D. The potential of dandelion in the fight against gastrointestinal diseases: a review. J Ethnopharmacol. 2022;293:115272.

30. Jin YR, Jin J, Piao XX, Jin NG. The effect of Taraxacum officinale on gastric emptying and smooth muscle motility in rodents. Neurogastroenterol Motil. 2011;23(8):766–e333.

31. Kimura Y, Sumiyoshi M. Effects of an Atractylodes lancea rhizome extract and a volatile component β-eudesmol on gastrointestinal motility in mice. J Ethnopharmacol. 2012;141(1):530–6.

32. Hossen MJ, Chou JY, Li SM, et al. An ethanol extract of the rhizome of Atractylodes chinensis exerts anti-gastritis activities and inhibits Akt/NF-κB signaling. J Ethnopharmacol. 2019;228:18–25.

33. Zhu B, Zhang QL, Hua JW, Cheng WL, Qin LP. The traditional uses, phytochemistry, and pharmacology of Atractylodes macrocephala Koidz.: a review. J Ethnopharmacol. 2018;226:143–67.

34. Singh K, Singh G, Bhushan B, et al. A comprehensive pharmacological review of Atractylodes macrocephala: traditional uses, phytochemistry, pharmacokinetics, and therapeutic potential. Pharmacol Res Mod Chin Med. 2024;10:100394.

35. Kwiatek MA, Roman S, Fareeduddin A, Pandolfino JE, Kahrilas PJ. An alginate-antacid formulation (Gaviscon Double Action Liquid) can eliminate or displace the postprandial “acid pocket” in symptomatic GERD patients. Aliment Pharmacol Ther. 2011;34(1):59–66.

36. Manabe N, Haruma K, Ito M, et al. Efficacy of adding sodium alginate to omeprazole in patients with nonerosive reflux disease: a randomized clinical trial. Dis Esophagus. 2012;25(5):373–80.

37. Chiu CT, Hsu CM, Wang CC, et al. Randomised clinical trial: sodium alginate oral suspension is non-inferior to omeprazole in the treatment of patients with non-erosive gastroesophageal disease. Aliment Pharmacol Ther. 2013;38(9):1054–64.

38. Panahi Y, Khedmat H, Valizadegan G, Mohtashami R, Sahebkar A. Efficacy and safety of Aloe vera syrup for the treatment of gastroesophageal reflux disease: a pilot randomized positive-controlled trial. J Tradit Chin Med. 2015;35(6):632–6.

39. Raj JP, Saxena U, Belhekar MN, et al. Efficacy and safety of GutGard® in managing gastroesophageal reflux-related symptoms: a phase III, single-centre, double-blind, randomized placebo-controlled trial. Complement Med Res. 2025;32(1):26–36.

40. Brown K, Owen P, et al. A polyphenol-based nutraceutical for chronic gastroesophageal reflux disease: an open-label comparative practice-based evaluation. Manuscript submitted for publication.